Loading…
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
90pct
102d open
vs 5,674 other S bills in the 119th — cohort avg 32d
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases. Also, the bill revises the NIH grants to require (1) the NIH, in considering grant renewal, to assess available information on the safety and efficacy of the investigational drugs; (2) grantees to promptly report available safety data from ongoing clinical trials; and (3) the NIH to determine the timeframe for enrollment in clinical trials for the investigational drugs. Additionally, every five years, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, for ALS and other rare neurodegenerative diseases. Each plan must include the FDA's previous actions and recommendations for improvements. Finally, the Government Accountability Office and the Department of Health and Human Services must report on the impacts of these grants.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2026 · third_quarter · Veterans
Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
Client expense: Not reported · Firm income: $24,000
Held at the desk.
Received in the House.
Message on Senate action sent to the House.
Passed Senate with an amendment by Voice Vote. (consideration: CR S4425-4426; text: CR S4425-4426)
Passed/agreed to in Senate: Passed Senate with an amendment by Voice Vote.
Placed on Senate Legislative Calendar under General Orders. Calendar No. 461.
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medical/Disease Research/Clinical Labs
Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
Client expense: Not reported · Firm income: $24,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
Client expense: Not reported · Firm income: $24,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
H.R. 8205/S.4472 - Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 - All provisions. H.R. 7779 - HEALTHY BRAINS Act - All Provisions H.R. 3864 - Protecting Health Care for All Patients Act of 2025 All provisions related to the banning of use of the quality-adjusted Life year valuation metric in coverage and payment determinations under federal health care programs. H.Res.449/S.Res 266 - Supports the designation of ALS Awareness Month - All Provisions. H.R.2560/S.830 - Lifespan Respite Care Reauthorization Act of 2025 - Provisions relating to amending the Public Health Service Act to extend funding for respite care through 2030 and broadening the definition of 'family caregiver' to include all unpaid individuals.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
H.R. 8205/S.4472 - Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 - All provisions. H.R. 7779 - HEALTHY BRAINS Act - All Provisions H.R. 3864 - Protecting Health Care for All Patients Act of 2025 All provisions related to the banning of use of the quality-adjusted Life year valuation metric in coverage and payment determinations under federal health care programs. H.Res.449/S.Res 266 - Supports the designation of ALS Awareness Month - All Provisions. H.R.2560/S.830 - Lifespan Respite Care Reauthorization Act of 2025 - Provisions relating to amending the Public Health Service Act to extend funding for respite care through 2030 and broadening the definition of 'family caregiver' to include all unpaid individuals.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medical/Disease Research/Clinical Labs
Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
Client expense: Not reported · Firm income: $24,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Veterans
Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
Client expense: Not reported · Firm income: $24,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
Client expense: Not reported · Firm income: $24,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medical/Disease Research/Clinical Labs
Expressed opposition to effort that caps indirect costs in NIH grants to 15% Supported efforts to add FSHD to the Peer Reviewed Medical Research Program Filed MDA Comments to U.S. Food and Drug Administration (FDA) on Impacts of Patient-Focused Drug Development Meetings RFI Led an ALS Organizations Letter to Speaker Johnson and Leader Jeffries Urging Swift Passage of ACT for ALS Reauthorization Act Sent an MDA Letter to Sens. Bill Cassidy and Bernie Sanders Re: Senate HELP Committee Markup of the ACT for ALS Reauthorization Act (S.4472) Filed MDA Comments to Centers for Disease Control and Prevention (CDC) on ICD-10 Code Classification of Ultra-Rare and Genetic Diseases Joined MDA Statement to Energy and Commerce Subcommittee on Health Markup of the ACT for ALS Reauthorization Act (H.R.8205) Filed MDA Comments to U.S. Food and Drug Administration on Plausible Mechanism Framework to Develop Individualized Therapies Sent MDA Comments in Support of ACT for ALS Reauthorization Act of 2026 Sent an MDA Statement on ACT for ALS Reauthorization Introduction Sent MDA Comments Re: Rare Disease Educational Materials from the Center for Drug Evaluation and Researchs Accelerating Rare Disease Cures Program and the Rare Disease Innovation Hub
Client expense: $60,000 · Firm income: Not reported
| Republican |
| PA |
| Edward J. Markey | Democratic | MA |
| Jeff Merkley | Democratic | OR |
| Jim Banks | Republican | IN |
| John Barrasso | Republican | WY |
| John R. Curtis | Republican | UT |
| Kirsten E. Gillibrand | Democratic | NY |
| Margaret Wood Hassan | Democratic | NH |
| Sheldon Whitehouse | Democratic | RI |
| Shelley Moore Capito | Republican | WV |
| Steve Daines | Republican | MT |
| Susan M. Collins | Republican | ME |
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE